Morgan Stanley reiterated their overweight rating on shares of Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) in a research report released on Tuesday, Marketbeat.com reports. They currently have a $38.00 price objective on the stock, down from their prior price objective of $47.00.

Other equities research analysts also recently issued reports about the company. BidaskClub upgraded Biohaven Pharmaceutical Holding Co from a buy rating to a strong-buy rating in a report on Thursday, September 28th. Piper Jaffray Companies reissued a buy rating and issued a $54.00 price objective on shares of Biohaven Pharmaceutical Holding Co in a research note on Tuesday, September 12th. Zacks Investment Research raised Biohaven Pharmaceutical Holding Co from a sell rating to a hold rating in a research note on Tuesday, August 22nd. Finally, Needham & Company LLC reduced their price objective on Biohaven Pharmaceutical Holding Co from $43.00 to $36.00 and set a buy rating for the company in a research note on Tuesday. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Biohaven Pharmaceutical Holding Co presently has an average rating of Buy and an average price target of $40.80.

Shares of Biohaven Pharmaceutical Holding Co (NASDAQ BHVN) traded up 0.09% during trading on Tuesday, hitting $32.09. The company had a trading volume of 4,745 shares. The stock’s market capitalization is $1.15 billion. The stock has a 50-day moving average of $35.80 and a 200 day moving average of $27.75. Biohaven Pharmaceutical Holding Co has a 12-month low of $17.00 and a 12-month high of $39.51.

TRADEMARK VIOLATION WARNING: This piece of content was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and republished in violation of US & international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/06/biohaven-pharmaceutical-holding-co-ltd-bhvn-earns-overweight-rating-from-morgan-stanley.html.

About Biohaven Pharmaceutical Holding Co

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Analyst Recommendations for Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN)

Receive News & Stock Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related stocks with our FREE daily email newsletter.